Affiliation:
1. Department of Pathology, University of Utah Health , Salt Lake City, UT , USA
2. ARUP Laboratories , Salt Lake City, UT , USA
Abstract
Abstract
Objectives
To determine the frequency of use of laboratory-developed tests (LDTs) in an academic medical center system.
Methods
Retrospective analysis of 2021 test order data from an academic medical center (hospital, outpatient clinics, and cancer center) was done. Measures included assay type, assay methodology, regulatory status, test order volume, inpatient vs outpatient setting, and provider medical specialty.
Results
Of the 3,016,928 tests ordered in 2021, 2,831,489 (93.9%) were tests cleared, approved, and/or authorized by the US Food and Drug Administration (FDA); 116,583 (3.9%) were LDTs; and 68,856 (2.3%) were standard methods. These test orders were performed using a total of 1,954 distinct assays. Of these, 983 (50.3%) were FDA assays, 880 (45.0%) were LDTs, and 91 (4.7%) were standard methods. Laboratory-developed tests were more commonly ordered in the outpatient vs inpatient setting and represented a higher proportion of the test volume at the cancer center compared with the university hospital (5.6% vs 3.6%, respectively). The top 167 LDT assays accounted for 90% of the LDT volume (104,996 orders). Among the 20 most frequently ordered LDTs were mass spectrometry assays and tests used in the care of immunocompromised patients. Internal/family medicine placed the greatest number of orders (1,044,642) and ordered one of the lowest proportions of LDTs (3.2%).
Conclusions
Laboratory-developed tests made up a small percentage of the total laboratory tests ordered within the academic health system studied.
Publisher
Oxford University Press (OUP)
Reference34 articles.
1. (PL 94-295, May 28, 1976) United States Statutes at Large;Medical Device Amendments of 1976,1976
2. Oversight of laboratory developed tests. Public meeting. Request for comments;US Food and Drug Administration;Fed Reg.,2010
3. FDA backs off plans to issue rules governing lab-developed tests;Burton,2016
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Modifications of FDA-cleared/approved tests;American Journal of Clinical Pathology;2023-07-14
2. Laboratory-developed tests: The forgotten majority;American Journal of Clinical Pathology;2023-07-14
3. Regulation of laboratory-developed tests: scoping the issue;American Journal of Clinical Pathology;2023-06-02